REAL-WORLD USE OF TPO RECEPTOR AGONISTS IN SECONDARY IMMUNE THROMBOCYTOPENIA ASSOCIATED WITH INDOLENT LYMPHOPROLIFERATIVE DISORDERS: A 12-YEAR MONOCENTRIC EXPERIENCE (SIE 2026) - Oct 6, 2026 - Abstract #SP026; "Complete response (≥100×10⁹/L) was achieved in 6/11 patients (55%), including 4 treated with eltrombopag and 2 with romiplostim...No patients re- ceived avatrombopag...In the era of fixed-duration targeted therapies, the role of long-term TPO-RAs should be balanced against thrombotic risk and treatment burden. Larger studies are needed to confirm these findings."
Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Immune Thrombocytopenic Purpura • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Myocardial Infarction • Thrombocytopenia • Thrombocytopenic Purpura • Waldenstrom Macroglobulinemia • CXCR4 • IGH • TP53
|
|
V. Innao; O. Bianco; V. Leotta; M. Di Giorgio; A. Barbagallo; A. Gorgone; M. Salerno; G. Uccello; A. Todaro; F. Lo Presti; R. Calogero; V. Uccellatore; U. Consoli
|